(Reuters) - Pfizer Inc’s (PFE.N) quarterly revenue missed analysts’ estimates on Tuesday, hurt by lower-than-expected sales of blockbuster breast cancer drug Ibrance and arthritis drug Xeljanz.
Ibrance raked in sales of $933 million in the first quarter, up 37.4 percent from a year earlier, but missed analysts’ estimates of $956.6 million, according to Thomson Reuters I/B/E/S.
The drug faces competition from Novartis’ (NOVN.S) Kisqali and Lilly’s (LLY.N) recently approved Verzenio.
Xeljanz, which is approved to treat rheumatoid arthritis and psoriatic arthritis, posted sales of $326 million, well below $398.5 million expected by analysts.
Shares of the largest U.S. drugmaker fell 1.67 percent to $36 in premarket trading on Tuesday.
Pfizer, which has been exploring options for its consumer healthcare business, said it expected to make a decision in 2018.
The company hoped to bring in $20 billion through an auction for the business, which includes Centrum vitamins and Advil painkillers.
Pfizer’s quarterly profit, however, topped Wall Street estimates on stronger-than-expected sales of pneumonia vaccine Prevnar. The company also reaffirmed its 2018 forecast.
Prevnar recorded sales of $1.38 billion, which was slightly better than what analysts were expecting.
Net profit rose to $3.56 billion, or 59 cents per share, in the latest quarter ended April 1 from $3.12 billion, or 51 cents per share, a year earlier.
Excluding items, the company earned 77 cents per share, topping estimates of 74 cents.
Total revenue rose 1 percent to $12.91 billion, while analysts were expecting $13.13 billion.
Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Sai Sachin Ravikumar and Anil D'Silva
Disclaimer: The views expressed in this article are those of the author and may not reflect those of Kitco Metals Inc. The author has made every effort to ensure accuracy of information provided; however, neither Kitco Metals Inc. nor the author can guarantee such accuracy. This article is strictly for informational purposes only. It is not a solicitation to make any exchange in commodities, securities or other financial instruments. Kitco Metals Inc. and the author of this article do not accept culpability for losses and/ or damages arising from the use of this publication.